drugset / Trial / NCT00013871

Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs

NCT00013871

Prevention

Summary

The purpose of this study is to determine if 2 doses of Pneumococcal Conjugate Vaccine (PCV) followed by 1 dose of Pneumococcal Polysaccharide Vaccine (PPV) in HIV-infected children on anti-HIV therapy is helpful and safe in fighting pneumococcal infections in this group of children. This study will also look at the protection provided by childhood vaccination against measles, pertussis, and hepatitis B virus. Pneumococcal infections are the most common AIDS-related infection in HIV-infected children. PCV may help reduce the chances of HIV-infected children getting pneumococcal infections. This study will look at whether pneumococcal vaccines are safe and effective in HIV-infected children receiving HAART. It will look at whether HIV-infected children are protected by childhood vaccines received previously and if more doses are safe and improve protection.

Timeline

Start
Primary completion
Completion
2004-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed Vaccine
Subject Hepatitis B vaccine Vaccine
Subject Measles-Mumps-Rubella Vaccine (Live) Vaccine
Subject Pneumococcal Conjugate Vaccine, Heptavalent Vaccine
Subject Pneumococcal Vaccine, Polyvalent (23-valent) Vaccine